Lansoprazole Evolugen (Lansoprazole)

Lansoprazole acts on the gastric proton pump pathway to reduce acid secretion in several acid‑related conditions.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal irritation.
• Erosive esophagitis: facilitates mucosal repair and symptom relief.
• Duodenal ulcer: promotes ulcer healing by decreasing gastric acidity.
• Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens.
• Zollinger‑Ellison syndrome: controls hyper‑gastrinemia and associated ulcer disease.

• Lansoprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces basal and stimulated gastric acid secretion, leading to an increase in gastric pH and providing a therapeutic environment for ulcer healing and symptom control.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild pain or pressure in the head.
• Diarrhea: loose, watery stools.
• Abdominal pain: discomfort or cramping in the stomach area.
• Nausea: feeling of sickness or urge to vomit.
• Flatulence: excess gas in the gastrointestinal tract.
• Constipation: infrequent or difficult bowel movements.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty.
• Clostridioides difficile infection: severe colitis presenting with diarrhea and abdominal pain.
• Hepatic enzyme elevation: increased liver function test results indicating possible liver stress.
• Hypomagnesemia: low magnesium levels that may cause muscle cramps or cardiac arrhythmia.
• Stevens‑Johnson syndrome: rare skin disorder with blistering and mucosal involvement.
• Interstitial nephritis: inflammation of kidney tissue leading to impaired renal function.

When prescribing or dispensing Lansoprazole, several safety considerations should be observed.

• Assess renal function: adjust use in patients with severe impairment.
• Monitor for infection: prolonged therapy may increase risk of gastrointestinal infections.
• Avoid long‑term use without supervision: may mask underlying disease and cause nutrient malabsorption.
• Review concomitant medications: potential for drug‑drug interactions.
• Evaluate bone health: long‑term use may be associated with reduced calcium absorption.
• Store at room temperature: keep in the original container, protect from moisture and light.

Lansoprazole can affect the pharmacokinetics of several medicines; interactions are classified by clinical significance.

Major Interactions (Avoid)

• Ketoconazole: reduced absorption and efficacy.
• Atazanavir: decreased antiviral activity.
• Clopidogrel: diminished antiplatelet effect.
• Warfarin: increased anticoagulant effect and INR.
• Methotrexate: heightened toxicity risk.

Moderate Interactions (Monitor Closely)

• Diazepam: increased plasma levels.
• Phenytoin: decreased concentration and efficacy.
• Digoxin: elevated serum levels.
• Iron supplements: reduced absorption of both agents.
• Vitamin B12: decreased absorption with prolonged use.